2 results
Not approvedWill not start
Primary:* To prove the superiority of a 48-weeks treatment with 3.2 g/day delayedreleasephosphatidylcholine (LT-02) versus placebo for the maintenance ofremission in patients with ulcerative colitis (UC)Secondary:* To study safety and tolerability…
Approved WMOCompleted
•To evaluate the efficacy of ASP8302 compared with placebo in subjects with Underactive Bladder (UAB)•To investigate the safety and tolerability of ASP8302 compared with placebo in subjects with UAB•To investigate the pharmacokinetics of ASP8302 in…